Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC revamps merger review

This article was originally published in The Tan Sheet

Executive Summary

Reforms to FTC's evaluation process for "second requests" in merger and acquisition transactions are intended to expedite such inquiries and to lower costs for the commission and companies involved. The reforms are in effect for all filings submitted on or after Feb. 17. Second requests are made when the agency seeks additional information about proposed transactions and occur in about 5% of merger evaluations, the commission says; more than half of such requests resulted in antitrust enforcement action in 2005. 1"Reforms to the Merger Review Process" include limiting the number of employees required to provide information and narrowing the time periods for which companies must provide documentation. While a typical M&A request takes 30 days to clear, second requests currently take up to six to nine months, costing the agency millions of dollars, FTC says...

You may also be interested in...



Coronavirus Pipeline: GSK And Clover Add To Collaborations

Companies continue to throw their hats into the ring against the virus, with strategies ranging from ‘off the shelf’ molecules to novel vaccine and anti-viral therapies

Switzerland And UK Work On Closer Medtech Ties As EU Links Fall Apart

Switzerland’s current economic and trading relationship with the UK is based on its MRA with the EU. So, where does this leave the two countries in trading with one another now each of their relationships with the EU are under threat?

AstraZeneca Looks To FluMist Experience In COVID-19 Efforts

The UK firm speaks about its efforts to tackle the virus as a recent spike in COVID-19 cases outside China heighten concerns.

Topics

UsernamePublicRestriction

Register

PS099112

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel